Thyroid Cancer in 2026 – The Year in on Paragraph

  • The year 2026 was a consolidation-and-de-escalation year for differentiated thyroid cancer (DTC) and a survival-data year for advanced disease
  • The single most practice-changing dataset is the final overall-survival analysis of LIBRETTO-531 in RET-mutant medullary thyroid cancer (MTC):
    • Presented at ESMO 2026:
      • Showing a ~ 66% reduction in the hazard of death with first-line selpercatinib
  • The first-ever ASCO guideline on systemic treatment (April 2026) codified a biomarker-first approach across DTC, poorly differentiated / high-grade, anaplastic (ATC) and medullary disease
  • Regulators expanded selpercatinib in both the US (FDA traditional, tissue-agnostic approval, July 2026) and the EU (EMA extension down to age 2 years for thyroid indications, March 2026)
  • For low-risk DTC, the 2026 evidence:
    • Active-surveillance cohorts extending to tumors > 1.5 cm and to 10 years
    • Lobectomy series and meta-analyses (including, provocatively, for sporadic MTC)
    • A large radiofrequency-ablation meta-analysis
    • A JAMA microsimulation estimating 72% to 94% overdiagnosis of US papillary cancers
      • All pushed in the same direction as the 2025 ATA DTC guideline (2025 context) that frames almost every 2026 paper
  • In ATC, lenvatinib + pembrolizumab produced a median OS of 13 months in a peer-reviewed phase 2 trial in BRAF wild-type metastatic disease, and neoadjuvant TKI + immunotherapy series and a preliminary EGFR-ADC trial suggested more unresectable tumors can be converted to resection
Screenshot

Leave a Reply